Nanobiotix Announces Advancement in NBTXR3 Development and Strategic Collaboration

Nanobiotix has reported significant progress in its global NBTXR3 development in collaboration with Janssen Pharmaceutica NV. The latest corporate strategy aims to support long-term growth through the global NBTXR3 partnership and further development of additional platforms.

Key updates include the agreed transfer of the Phase 3 head and neck cancer trial sponsorship, removal of futility analysis for streamlined regulatory processes, and the initiation of a Phase 2 lung cancer study following FDA approval.

The company remains focused on leveraging NBTXR3, a nanoparticle-based radioenhancer, to enhance treatment for cancer patients receiving radiotherapy. This collaboration with Janssen highlights significant operational milestones, including successful setup of joint strategic committees and the first milestone payment of $20M from Janssen.

Nanobiotix anticipates sustaining its cash runway beyond 3Q2025. The company expects further updates on NBTXR3 and other platforms by 2H2024.